Literature DB >> 14578374

Tyrosine 116 of the herpes simplex virus type 1 IEalpha22 protein is an ocular virulence determinant and potential phosphorylation site.

Curtis R Brandt1, Aaron W Kolb.   

Abstract

PURPOSE: To determine whether tyrosine 116 of the HSV-1 alpha22 protein is involved in virulence and is a potential phosphorylation site.
METHODS: Site-directed mutagenesis was used to revert the Y116C mutation in the alpha22 gene of the strain OD4 to wild type (C116Y), and the effect of virulence was tested by using a marker transfer-infection protocol in mice. Immunoblot analysis, tryptic phosphopeptide mapping, and phosphotyrosine pulldown-immunoblot protocols were used to assess the OD4 alpha22 isoforms.
RESULTS: Reversion of the Y116C mutation resulted in a significant increase in the severity of ocular disease compared with the OD4 virus alone. Reversion of the Y116C and a previously identified mutation (S34A) together did not alter the severity of virulence compared with either mutation alone. Immunoblot analysis revealed a loss or reduction in alpha22 isoforms in the OD4 virus compared with wild type (CJ394 virus). The OD4 virus had numerous alterations in the alpha22 tryptic phosphopeptide pattern, including loss of specific peptides and shifts in the position of several peptides. Phosphotyrosine pulldowns revealed a loss of one or more isoforms and shifts in the apparent size of others.
CONCLUSIONS: The data indicate that Y116 is a determinant of peripheral virulence in mice and that mutations at S34 and Y116 affect virulence independently. The data also show that the S34 and Y116 mutations substantially alter phosphorylation of the alpha22 protein, that Y116 is a potential phosphorylation site, and that the alpha22 protein contains at least two phosphotyrosines. These results are the first to show that mutation of a specific tyrosine in the alpha22 protein is associated with virulence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578374     DOI: 10.1167/iovs.03-0582

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant.

Authors:  Aaron W Kolb; Timothy R Schmidt; David W Dyer; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-28       Impact factor: 4.799

2.  A truncation mutation of the neurovirulence ICP22 protein produced by a recombinant HSV-1 generated by bacterial artificial chromosome technology targets infected cell nuclei.

Authors:  Robert N Bowles; John A Blaho
Journal:  J Neurovirol       Date:  2011-12-03       Impact factor: 2.643

Review 3.  The herpes simplex virus type 1 infected cell protein 22.

Authors:  Fu-sen Lin; Qiong Ding; Hong Guo; Alan C Zheng
Journal:  Virol Sin       Date:  2010-02-12       Impact factor: 4.327

4.  Mapping Murine Corneal Neovascularization and Weight Loss Virulence Determinants in the Herpes Simplex Virus 1 Genome and the Detection of an Epistatic Interaction between the UL and IRS/US Regions.

Authors:  Kyubin Lee; Aaron W Kolb; Inna Larsen; Mark Craven; Curtis R Brandt
Journal:  J Virol       Date:  2016-08-26       Impact factor: 5.103

5.  Origin of expression of the herpes simplex virus type 1 protein U(S)1.5.

Authors:  J Jason Bowman; Priscilla A Schaffer
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

6.  Quantitative Trait Locus Based Virulence Determinant Mapping of the HSV-1 Genome in Murine Ocular Infection: Genes Involved in Viral Regulatory and Innate Immune Networks Contribute to Virulence.

Authors:  Aaron W Kolb; Kyubin Lee; Inna Larsen; Mark Craven; Curtis R Brandt
Journal:  PLoS Pathog       Date:  2016-03-10       Impact factor: 6.823

7.  Loss of ICP22 in HSV-1 Elicits Immune Infiltration and Maintains Stromal Keratitis Despite Reduced Primary and Latent Virus Infectivity.

Authors:  Harry H Matundan; Ujjaldeep Jaggi; Shaohui Wang; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2019-08-01       Impact factor: 4.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.